- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond HER2: Targeting the ErbB receptor family in breast cancer
Authors
Keywords
-
Journal
CANCER TREATMENT REVIEWS
Volume 109, Issue -, Pages 102436
Publisher
Elsevier BV
Online
2022-07-15
DOI
10.1016/j.ctrv.2022.102436
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
- (2022) Alison M Schram et al. Cancer Discovery
- LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
- (2022) A. Prat et al. ANNALS OF ONCOLOGY
- 166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
- (2022) P. Schmid et al. ANNALS OF ONCOLOGY
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
- (2022) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- 30 years of HER3: From basic biology to therapeutic interventions
- (2021) Heidi M. Haikala et al. CLINICAL CANCER RESEARCH
- Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2021) Binghe Xu et al. LANCET ONCOLOGY
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
- (2021) Komal Jhaveri et al. CLINICAL CANCER RESEARCH
- TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).
- (2021) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
- (2020) M. Kundranda et al. ANNALS OF ONCOLOGY
- Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
- (2020) Yingnan Si et al. ENGINEERING IN LIFE SCIENCES
- Target HER four in breast cancer?
- (2019) Gero Brockhoff Oncotarget
- TARGETING EGFR PATHWAY IN METASTATIC COLORECTAL CANCER- TUMOUR HETEROGENIETY AND CONVERGENT EVOLUTION
- (2019) Khurum Khan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
- (2019) Nicolas Kiavue et al. ONCOGENE
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
- (2019) Amaia Eleonora Maennling et al. Cancers
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
- (2018) J Remon et al. ANNALS OF ONCOLOGY
- Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-LineRASWild-Type Metastatic Colorectal Cancer
- (2018) Andrew G. Hill et al. CLINICAL CANCER RESEARCH
- Targeting EGFR in Lung Cancer: Current Standards and Developments
- (2018) Asunción Díaz-Serrano et al. DRUGS
- Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
- (2018) Andreas Schneeweiss et al. INVESTIGATIONAL NEW DRUGS
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells
- (2017) Hui K. Gan et al. Nature Reviews Clinical Oncology
- A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.
- (2017) M. J. Higgins et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells
- (2016) Shogo Okazaki et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
- (2016) Denise A. Yardley et al. Clinical Breast Cancer
- N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy
- (2016) Jennifer A. Crozier et al. Clinical Breast Cancer
- A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
- (2016) Konstantinos Tryfonidis et al. EUROPEAN JOURNAL OF CANCER
- Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
- (2016) Nadia Harbeck et al. LANCET ONCOLOGY
- First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
- (2015) D. Meulendijks et al. CLINICAL CANCER RESEARCH
- Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
- (2015) J.M. Nabholtz et al. INTERNATIONAL JOURNAL OF CANCER
- The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer
- (2015) Saori Fujiwara et al. Oncotarget
- Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
- (2015) Siti Norasikin Mohd Nafi et al. Oncotarget
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Molecular Pathways: HER3 Targeted Therapy
- (2014) K. Gala et al. CLINICAL CANCER RESEARCH
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
- (2014) J. J. Tao et al. Science Signaling
- Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
- (2013) Y H Park et al. BRITISH JOURNAL OF CANCER
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
- (2012) Martin Schuler et al. BREAST CANCER RESEARCH AND TREATMENT
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study
- (2011) C. K. Osborne et al. CLINICAL CANCER RESEARCH
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival
- (2010) Connie G. Chiu et al. ANNALS OF SURGERY
- Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) M. Cristofanilli et al. CLINICAL CANCER RESEARCH
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
- (2009) M. D. Green et al. ANNALS OF ONCOLOGY
- The upgraded role of HER3 and HER4 receptors in breast cancer
- (2009) Angelos K. Koutras et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
- Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms
- (2009) M Hollmén et al. ONCOGENE
- Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
- (2009) Amir Harandi et al. Journal of Oncology
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
- (2008) Maura N. Dickler et al. BREAST CANCER RESEARCH AND TREATMENT
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now